StockNews.com Begins Coverage on Aptose Biosciences (NASDAQ:APTO)

StockNews.com started coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a report issued on Thursday morning. The firm issued a hold rating on the biotechnology company’s stock.

Separately, HC Wainwright reissued a buy rating and issued a $7.00 target price on shares of Aptose Biosciences in a report on Friday, June 14th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, Aptose Biosciences currently has an average rating of Moderate Buy and a consensus price target of $9.00.

Aptose Biosciences Price Performance

Shares of NASDAQ APTO opened at $0.41 on Thursday. The company has a market cap of $7.34 million, a price-to-earnings ratio of -0.07 and a beta of 1.25. The stock’s 50-day moving average is $0.45 and its two-hundred day moving average is $0.89. Aptose Biosciences has a 1-year low of $0.33 and a 1-year high of $3.32.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last issued its earnings results on Thursday, August 8th. The biotechnology company reported ($0.43) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.58) by $0.15. Equities research analysts anticipate that Aptose Biosciences will post -2.62 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Aptose Biosciences

An institutional investor recently bought a new position in Aptose Biosciences stock. Armistice Capital LLC acquired a new position in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) in the second quarter, according to its most recent disclosure with the SEC. The firm acquired 1,713,000 shares of the biotechnology company’s stock, valued at approximately $1,300,000. Armistice Capital LLC owned 9.46% of Aptose Biosciences at the end of the most recent quarter. 26.62% of the stock is currently owned by institutional investors and hedge funds.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.